Diovan

Diovan. It is the brand name for the angiotensin II receptor blocker (ARB) medication valsartan, primarily used to treat hypertension, heart failure, and to improve survival following a myocardial infarction. Developed by the Swiss pharmaceutical company Novartis, it acts by selectively blocking the angiotensin II type 1 receptor, a key component of the renin–angiotensin–aldosterone system. Its clinical efficacy and safety profile have been established in major trials such as VALUE and VALIANT, solidifying its role in modern cardiovascular therapy.

Medical uses

Diovan is indicated for the management of essential hypertension in adults and children over six years old, often as a first-line agent or in combination with other antihypertensives like hydrochlorothiazide. It is also approved for the treatment of systolic dysfunction heart failure, typically in conjunction with standard therapies including beta blockers and diuretics, to reduce cardiovascular mortality and hospitalizations. Furthermore, it is used in post-myocardial infarction patients with clinical signs of heart failure or left ventricular dysfunction, as demonstrated in the VALIANT trial conducted across numerous centers including the Brigham and Women's Hospital. Off-label, it may be considered in certain cases of diabetic nephropathy or migraine prophylaxis, though evidence is less robust than for losartan or candesartan in these areas.

Adverse effects

Common adverse effects include dizziness, headache, viral infection, fatigue, and abdominal pain. Serious but rare risks involve angioedema, hypotension, hyperkalemia, and impaired renal function, particularly in patients with renal artery stenosis or those concurrently using NSAIDs or potassium-sparing diuretics like spironolactone. As a pregnancy category D drug, its use during the second and third trimesters can cause injury and death to the developing fetus, leading to conditions such as oligohydramnios. The U.S. Food and Drug Administration has also issued safety alerts regarding the potential presence of nitrosamine impurities, like NDMA, in certain batches of valsartan from manufacturers such as Zhejiang Huahai Pharmaceutical.

Pharmacology

Valsartan is a potent and selective antagonist of the angiotensin II type 1 (AT1) receptor, which is part of the renin–angiotensin–aldosterone system. By blocking the action of angiotensin II on vascular smooth muscle and the adrenal gland, it inhibits vasoconstriction and the secretion of aldosterone, leading to decreased blood pressure and reduced cardiac afterload. It is administered as a prodrug but does not require metabolic activation, exhibiting minimal interaction with the cytochrome P450 system. Its pharmacokinetic profile shows linear absorption, with peak plasma concentrations reached within 2-4 hours, and it is primarily eliminated via biliary excretion, with a smaller fraction cleared renally.

History

Valsartan was discovered and developed by researchers at the pharmaceutical company Ciba-Geigy, which later merged with Sandoz to form Novartis. It received its first approval for hypertension from the U.S. Food and Drug Administration in 1996. Its indications were later expanded following the results of the landmark VALUE trial in hypertension and the VALIANT trial in post-myocardial infarction care, which compared it against captopril. In 2014, a combination drug containing valsartan and sacubitril, named Entresto, was approved for heart failure with reduced ejection fraction, representing a significant advancement. Global supply was impacted in 2018 when the European Medicines Agency and other regulators recalled numerous batches due to contamination concerns originating from API manufacturers in China.

Society and culture

As a widely prescribed ARB, Diovan has been a major commercial product for Novartis, generating significant revenue and featuring prominently in pharmaceutical marketing. Its patent expiration in major markets like the United States and the European Union led to the introduction of numerous generic versions from companies such as Teva Pharmaceutical Industries and Mylan. The valsartan contamination scandal prompted widespread regulatory scrutiny by bodies including the World Health Organization and led to numerous lawsuits. The drug is on the World Health Organization's List of Essential Medicines, underscoring its importance in global public health for managing cardiovascular disease, a leading cause of mortality worldwide. Category:Antihypertensive agents Category:Novartis brands Category:Angiotensin II receptor antagonists